USO DA ESPIRONOLACTONA NO TRATAMENTO DA ACNES DA MULHER ADULTA (AMA) OCASIONADA PELA SÍNDROME DO OVÁRIO POLICÍSTICO – SOP

Abstract

This work aims to analyze the use of spironolactone in the treatment of acne in adult women (AMA), particularly when associated with Polycystic Ovary Syndrome (PCOS). AMA is characterized by the late onset of acne in women over 25 years of age, generally linked to hormonal imbalances caused by hyperandrogenism. PCOS, a common endocrine disorder, increases the levels of androgens, such as testosterone, favoring increased skin oiliness and, consequently, the appearance of acne. Spironolactone, a potassium-sparing diuretic, is effective in treating AMA due to its action of antagonizing androgen receptors and inhibiting the 5-alpha-reductase enzyme, reducing sebum production and inflammation associated with acne. For the study, an integrative literature review was carried out, examining articles published between 2008 and 2024, in addition to data from health bodies and monographs on the medicine. The results highlight spironolactone as an efficient therapeutic option for adult women with PCOS, providing relief from symptoms such as excessive oiliness, hyperkeratinization and the appearance of new acne lesions. Although the treatment may have adverse effects, such as hyperkalemia and menstrual irregularities, adequate medical monitoring and the choice of adjusted doses ensure the safety and effectiveness of the therapy.